InMed is getting some major coverage from their recent news of their patent application filing.
Recently MMJReporter.com covered InMed Pharmaceuticals.
Here is an excerpt from the article:
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) was covered in a recent article of CFN Media Group. The entity focused on company’s biosynthesis program and the way it could help resolve numerous vexing issues with cannabis drug advancement.
... InMed Pharma has advanced a robust, high-yield biosynthesis procedure for manufacturing all more than 90 naturally-occurring CBDs. The procedure combines the known efficacy and inherent safety of natural drug structures with the control, quality and convenience of a lab-based manufacturing procedure. In other words, the procedure is merging the entourage impact of the botanical medication with the need for accuracy and consistency within the medical community.
READ THE REST OF THE ARTICLE AT MMJREPORTER.COM
Read More
INMED PHARMACEUTIC COM NPV (CSE: IN OTCBB: IMLFF) Closes In Green
